How acute myeloid leukemia (AML) escapes from FMS-related tyrosine kinase 3 (FLT3) inhibitors? Still an overrated complication?

Perrone, S; Ottone, T; Zhdanovskaya, N; Molica, M

Molica, M (通讯作者)，S Eugenio Hosp, Hematol Unit, ASL Roma 2, I-00144 Rome, Italy.;Molica, M (通讯作者)，S Eugenio Hosp, Hematol Unit, Piazza Umanesimo 10, I-00144 Rome, Italy.

CANCER DRUG RESISTANCE, 2023; 6 (2): 223

Abstract

FMS-related tyrosine kinase 3 (FLT3) mutations, present in about 25%-30% of acute myeloid leukemia (AML) patients, constitute one of the most frequent......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索